Curated news and analysis on clinical trials, drug approvals, and medical research.
The FDA rejected accelerated approval for Disc Medicine's bitopertin for erythropoietic protoporphyria, citing insufficient evidence that biomarker reductions translate to clinical benefit. The agency wants to see results from the ongoing Phase 3 APOLLO trial before considering traditional approval, pushing any decision to at least mid-2027. Disc Medicine plans to address FDA concerns with APOLLO data expected in Q4 2026.
Despite guidelines recommending broad molecular profiling for precision oncology, biomarker testing faces significant implementation barriers including insurance coverage limitations, lengthy turnaround times, and tissue adequacy issues. Studies show most patients lack biomarker results at initial consultation, with up to 43% having insufficient tissue for genotyping in NSCLC cases.
AI systems in pharmaceutical companies are acting as silent strategists, introducing hidden behavioral nudges that influence drug development decisions. These systems can create biases favoring incremental innovation over novel approaches, potentially reshaping pipeline strategy and portfolio composition. The distinction between intentional and emergent algorithmic nudges represents a new governance challenge for the industry.
A Wisconsin man faces over a dozen felony charges for allegedly growing marijuana and possessing firearms near a Girl Scout camp, while a Massachusetts man was arrested on drug and firearm charges. The Wisconsin suspect could face over 160 years in prison if convicted on all counts.
The FDA has approved Optune Pax, a Tumor Treating Fields device, for use with chemotherapy in locally advanced pancreatic cancer. The approval is based on phase 3 trial data showing improved overall survival and pain progression outcomes. This marks the first new treatment approach for this patient population in approximately 30 years.
Inovio Pharmaceuticals faces a class action lawsuit alleging false statements about manufacturing deficiencies affecting its INO-3107 drug candidate. The lawsuit claims the company exaggerated its ability to file a BLA by mid-2024 and misled investors about accelerated FDA review prospects. Following FDA acceptance for standard rather than accelerated review, Inovio's stock dropped 24.45%.
The European Union has approved a higher 7.2 mg maintenance dose for Wegovy (semaglutide) for chronic weight management. Clinical trial data shows mean weight loss of 20-21% with the 7.2 mg dose compared to 17-18% with the standard 2.4 mg dose. The approval provides clinicians with an on-label option for patients with inadequate response to standard dosing.
Atezolizumab combined with chemotherapy shows significant benefits in dMMR/MSI-H colorectal cancer. In stage III disease, the ATOMIC trial demonstrated improved 3-year DFS (86.3% vs 76.2%) with atezolizumab plus mFOLFOX6. For metastatic disease, the COMMIT trial showed superior PFS (24.5 vs 5.3 months) with atezolizumab, bevacizumab, and FOLFOX versus atezolizumab monotherapy.
Morgan Stanley raised its Novartis price target to $170 from $143 with an Overweight rating, while TD Cowen increased its target to $180 from $160 with a Hold rating. Morgan Stanley sees $23 billion in risk-adjusted potential from nine pipeline assets, with additional upside in success scenarios.
Multiple research teams have developed innovative diabetes treatments including implantable insulin-producing cell devices, an oral insulin delivery platform using peptides, and a biological implant that functions as an autonomous artificial pancreas. These approaches have shown promising results in animal studies, with some devices maintaining glucose control for 90 days or more without immune suppression. The technologies represent potential alternatives to daily insulin injections for millions of diabetes patients worldwide.
New research reveals metformin regulates blood sugar through brain pathways involving the Rap1 protein in the hypothalamus. The study shows suppressing Rap1 in the brain prevents metformin from lowering blood sugar in diabetic mice. These findings could lead to new diabetes treatments targeting this brain pathway.
Avidity Biosciences announced promising Phase 1/2 trial results for its myotonic dystrophy type 1 drug delpacibart etedesiran, showing 40% reduction in DMPK mRNA and functional improvements. The therapy has received multiple regulatory designations and is now in Phase 3 testing with data expected in late 2026. The company's stock has surged 128% over the past year despite reporting a net loss of approximately $550 million.
New York City has launched its first affordable housing project using a new 90-day expedited approval process, with an 84-unit Bronx development marking the debut of voter-approved reforms. The Powerhouse Apartments will transform a vacant city-owned lot into fully affordable housing with community amenities, cutting review time from seven months to just 90 days.
The ProSense Cryoablation System achieved an 83.9% recurrence-free rate in kidney cancer patients after 4 years in the ICESECRET trial. The system treats small renal masses up to 5 cm and is approved in multiple global markets. Detailed results will be presented at the European Conference on Interventional Oncology in April 2026.
Eli Lilly has acquired rights to CSL's IL-6 inhibitor clazakizumab in a $100 million deal, expanding its cardiometabolic pipeline. The monoclonal antibody targets chronic inflammation, particularly in cardiovascular conditions. This move follows Lilly's successful obesity and diabetes drugs that drove $65.1 billion in 2025 revenue.
A new study of over 246,000 heart disease patients shows the shingles vaccine reduces major cardiovascular events by 46% and death by 61% within one year. The protective effects are comparable to quitting smoking and support existing vaccine recommendations for adults over 50. The findings will be presented at the American College of Cardiology's annual meeting.
Kodiak Sciences' experimental drug Zenkuda achieved 62.5% response rate in diabetic retinopathy trial with 85% reduction in sight-threatening complications. The company plans to accelerate FDA submission while preparing for wet AMD study readout in Q3 2026. Shares surged 68.6% following the positive late-stage results.
Cardinal Health has recalled certain lots of Webcol Large Alcohol Prep Pads due to potential contamination with Paenibacillus phoenicis bacteria. The affected pads were distributed between September 2025 and February 2026 and pose infection risks, particularly for immunocompromised individuals. The FDA is aware of the voluntary recall.
Research reveals how ectopic NMDA receptor expression in triple-negative breast cancer triggers autoimmune disease through antibody maturation. The study shows NMDAR expression recruits B cells and drives affinity maturation, producing antibodies that can cross the blood-brain barrier and cause neurological symptoms while constraining tumor growth.
Quoin Pharmaceuticals has secured Orphan Drug Designations for QRX003 in the U.S. and Europe for Netherton Syndrome, while advancing regulatory pathways in Japan and Saudi Arabia. The company reported clinical progress including expansion of pediatric studies and potential for a Priority Review Voucher worth up to $200 million.
